Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Merck Group

Tracked across 33 events · 1948 articles · First seen Mar 09, 2018 · Last active Sep 23, 2026

Sentiment
20
Attention
8
Events
33
Relationships
92
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
8 65
Business
Impact: Merck Group is acquiring Bio-Techne — Bio-Techne Diagnostics Corporation to expand its life sciences business, reduce reliance on marketed drugs, and strengthen its position in high-growth areas like multi-omics and cell and gene therapy. This acquisition is its largest in over a decade and is expected to be immediately accretive to sales growth and EBITDA pre margin.
Jun 25, 2026 · 21 articles
3 60
Regulatory
Impact: Merck Group received FDA Breakthrough Therapy designation for its investigational drug enpatoran, a key regulatory milestone that could expedite development and approval, potentially boosting its immunology pipeline and market position.
Jul 08, 2026 · 6 articles
4 40
Business
Impact: Merck is the central company, reporting strong Q2 results and raising revenue guidance. Its stock rose 0.6% in early trading, reflecting positive market reception.
Aug 04, 2026 · 6 articles
7 90
Tech
On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran autogene, combined with Merck's immunotherapy Pembrolizumab, met its primary and secondary endpoints in a Phase 3 trial involving 1,137 patients…
Impact: Merck co-developed the vaccine and provided Pembrolizumab, which is central to the combination. The success strengthens its oncology franchise and provides a new growth opportunity as Pembrolizumab faces patent expiration later this decade.
Aug 19, 2026 · 126 articles
3 30
Business
Impact: Merck Group>>> committed globally to Veeva Vault CRM as part of its digital initiatives, aiming to support consistent processes and data connectivity across functions.
May 27, 2026 · 6 articles
7 20
Accidents
Impact: Merck Group's Ervebo vaccine is being deployed in the outbreak response, potentially increasing sales. However, its efficacy against the Bundibugyo strain is unproven, and the trial outcome will be critical.
Aug 01, 2026 · 301 articles
4 60
Tech
Impact: Merck Group is listed among the top companies in the epigenetics market, suggesting its involvement and potential for growth within this expanding sector.
Jun 26, 2026 · 6 articles
3 50
Business
Impact: Merck Group is mentioned as a top company in the Air Quality Monitoring Systems Market, indicating its participation in a growing sector.
Jun 09, 2026 · 6 articles
6 -10
Domestic
Impact: Manufacturer of MMR vaccine, faces potential demand for separate vaccines, but no evidence supports splitting. May face regulatory and financial hurdles.
Aug 10, 2026 · 266 articles
4 -10
Business
Impact: Merck markets Keytruda, the originator biologic facing patent cliff; the entry of biosimilars like QL2107 will erode its market share and revenue.
Sep 03, 2026 · 6 articles
2 40
Business
Impact: Affiliate Lamond Ventures co-led the round, reflecting Merck's strategic interest in genetic medicine.
Jul 07, 2026 · 6 articles
8 15
Accidents
Impact: Manufacturer of RVSV-ZEBOV vaccine, which is being considered for cross-protection trials. Its vaccine could play a role in the response, benefiting its reputation.
Mar 09, 2018 · 543 articles
4 20
Tech
Impact: Merck Group executives are participating in the summit, with Anna Guenter delivering a keynote on AI-ready leadership.
Jun 18, 2026 · 7 articles
3 30
International
Impact: Announced plans to allow generic production of alimatravir, potentially expanding market access.
Jul 21, 2026 · 68 articles
7 30
Domestic
Impact: Jumped 10.3% on vaccine data, positive for its Keytruda franchise.
Aug 19, 2026 · 133 articles
4 -20
Regulatory
Impact: Merck faces increased competition in the HIV treatment market as Gilead's Bixlenvo offers a new once-daily option, potentially impacting sales of Merck's Idvynso.
Aug 27, 2026 · 6 articles
4 5
Regulatory
Prime Minister Narendra Modi chaired a semiconductor roundtable with leading global and Indian semiconductor CEOs at Seva Teerth in New Delhi on September 16, 2026. Modi urged industry leaders to participate in the next phase…
Impact: Merck attended the roundtable, reflecting interest in supplying materials to India's growing semiconductor industry.
Sep 16, 2026 · 24 articles
4 10
Business
Impact: Merck's Keytruda is the comparator in the trial, and the failure of volrustomig may reinforce the competitive position of Keytruda in lung cancer treatment.
Aug 17, 2026 · 20 articles
6 10
Business
Impact: Peer comparison; slower growth and lower valuation highlight Lilly's premium, but Merck remains a stable large-cap pharma.
Aug 23, 2026 · 6 articles
8 20
Business
Impact: Merck Group agreed to acquire Bio-Techne — Bio-Techne Diagnostics.
Jun 24, 2026 · 57 articles
6 15
Regulatory
Impact: Signed an MoU with Tata Group to support semiconductor ecosystem development in India.
Jun 30, 2026 · 69 articles
4 30
Business
Impact: Merck's Lipfendra, the first FDA-approved PCSK9 pill, represents a competitive threat to Scribe's injectable therapy. Merck's innovation underscores the competitive landscape.
Jul 06, 2026 · 25 articles
2 0
Regulatory
Surrozen, Inc. announced the submission of an Investigational New Drug (IND) application to the U.S. United States — Food and Drug Administration for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody, for the treatment…
Impact: Merck is mentioned as having a competing Wnt agonist, MK-3000, which has shown proof of concept in DME. This provides competitive context but does not directly impact Merck's operations.
Sep 08, 2026 · 7 articles
6 5
Business
SemiconductorCON India 2026, the fifth edition of India's flagship semiconductor conference, was held at Yashobhoomi in New Delhi from September 17 to 19, 2026, inaugurated by Prime Minister Narendra Modi. The event, organized by the…
Impact: Participated in the event, representing materials suppliers interested in India's semiconductor growth.
Sep 14, 2026 · 167 articles
2 40
Business
Impact: Merck Group is mentioned as a former employer of Beyang's team, lending expertise but not directly affected by the financing.
Jul 20, 2026 · 6 articles
2 5
Business
The Hashgraph Association (THG), a Swiss Web3 and AI engineering company building on Hedera distributed ledger technology, announced that its IDTrust self-sovereign identity platform has been validated and officially listed on the IBM Cloud Catalog.…
Impact: Merck Group is cited as a prior THG partner on EU Digital Product Passports, providing context rather than direct event impact.
Sep 23, 2026 · 11 articles
2 0
Business
Impact: Merck Group is mentioned as a customer of Syngene, but the event has no direct impact on the company.
Jul 01, 2026 · 6 articles
2 0
Business
Impact: Mentioned as a Benchling customer, indicating Benchling's credibility but not directly affected by this event.
Aug 17, 2026 · 6 articles
0 0
Business
Impact: Merck is a partner of Ascentage Pharma, but this event does not directly involve Merck.
Jul 26, 2026 · 6 articles
2 0
Business
Apr 07, 2026 · 6 articles
+ 3 more events View on Dashboard
ERGEN INTELLIGENCE
Track Merck Group live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.